Department of Cardiovascular Medicine, Chonnam National University Hospital, Gwangju, Korea; Department of Cardiovascular Medicine, Chonnam National University Hwasun Hospital, Hwasun, Jeollanam-do, Korea.
Department of Cardiovascular Medicine, Chonnam National University Hospital, Gwangju, Korea; Department of Cardiovascular Medicine, Chonnam National University Medical School, Gwangju, Korea.
Mayo Clin Proc. 2024 Oct;99(10):1577-1588. doi: 10.1016/j.mayocp.2024.03.026. Epub 2024 Aug 2.
To investigate the incidence, characteristics, and outcomes of COVID-19 vaccine-related pericarditis (VRP) without myocarditis, we analyzed nationwide Korean data.
This is a retrospective nationwide report including all vaccinated Koreans with COVID-19 vaccine of any platform (BNT162b2, mRNA-1273, ChAdOx1, or Ad26.COV2.S) from February 26 to December 31, 2021. We analyzed the confirmed cases of COVID-19 VRP by the Expert Adjudication Committee. The incidence, clinical characteristics, and outcomes of COVID-19 VRP were analyzed.
Among 44,322,068 Koreans with least one dose of COVID-19 vaccination, COVID-19 VRP was confirmed in 179 cases, with 1.73 per million shots (95% CI, 1.48 to 2.00 per million shots). The incidence of VRP was significantly higher in males than females (2.01 per 1 million doses vs 1.45 per 1 million doses, respectively; P=.029), in mRNA vaccines than in other vaccines (2.09 per 1 million doses vs 0.36 per 1 million doses, respectively; P<.001), and in those younger than 40 years of age than those older than 40 years of age (3.52 per 1 million doses vs 0.89 per 1 million doses, respectively; P<.001). The incidence of VRP was highest in males between the ages of 12 and 17 years (7.38 per 1 million doses; 95% CI, 2.01 to 16.07). Although there was no case of mortality, hemodynamically significant pericardial effusion requiring pericardial drainage was noted in 10 cases (5.6%).
COVID-19 VRP was very rare and developed mainly in association with mRNA vaccines, especially in males younger than 40 years of age. The clinical course of VRP was excellent, and there were no cases of mortality. However, the development of hemodynamically significant pericardial effusion should be carefully monitored.
为了研究 COVID-19 疫苗相关心肌炎（VRP）而无心肌炎的发病率、特征和结局，我们分析了全国性的韩国数据。
这是一项回顾性全国性报告，包括自 2021 年 2 月 26 日至 12 月 31 日期间接种过任何平台（BNT162b2、mRNA-1273、ChAdOx1 或 Ad26.COV2.S）的所有 COVID-19 疫苗的韩国人。我们通过专家裁决委员会分析了 COVID-19 VRP 的确诊病例。分析了 COVID-19 VRP 的发病率、临床特征和结局。
在至少接种过一剂 COVID-19 疫苗的 44322068 名韩国人中，确诊了 179 例 COVID-19 VRP，每百万剂 1.73 例（95%CI，每百万剂 1.48 至 2.00 例）。男性的 VRP 发病率明显高于女性（分别为每百万剂 2.01 例和每百万剂 1.45 例；P=.029），mRNA 疫苗的发病率高于其他疫苗（分别为每百万剂 2.09 例和每百万剂 0.36 例；P<.001），年龄小于 40 岁的发病率高于年龄大于 40 岁的（分别为每百万剂 3.52 例和每百万剂 0.89 例；P<.001）。男性 12 至 17 岁的 VRP 发病率最高（每百万剂 7.38 例；95%CI，2.01 至 16.07）。虽然没有死亡病例，但有 10 例（5.6%）需要心包引流的血流动力学显著心包积液。
COVID-19 VRP 非常罕见，主要与 mRNA 疫苗有关，尤其是 40 岁以下的男性。VRP 的临床过程良好，无死亡病例。然而，应密切监测血流动力学显著心包积液的发展。
